Jordan Park

Jordan Park

Healthcare & Biotech Analyst

Healthcare and biotech analyst focused on pharma pipelines, medtech adoption curves, and reimbursement dynamics. Former clinical research coordinator and later equity research analyst. Writes thesis-driven pieces that connect clinical catalysts, competitive landscapes, and valuation scenarios.

Articles 769

Comparing IGIB and VCIT: Variation in Investment Grade Corporate Bond Strategies
Dec 29, 2025 Business News

Comparing IGIB and VCIT: Variation in Investment Grade Corporate Bond Strategies

A detailed look at how diversification, sector exposure, and fund management impact intermediate-term corporate bond ETFs

The iShares 5-10 Year Investment Grade Corporate Bond ETF (IGIB) and the Vanguard Intermediate-Term Corporate Bond ETF (VCIT) both invest in intermedi...

Dec 29, 2025 Finance

Strategy Inc. Adds Over 1,200 Bitcoin Despite Criticism From Peter Schiff

The firm's ongoing Bitcoin accumulation raises concerns amid significant stock depreciation and skepticism about returns

Strategy Inc. has expanded its Bitcoin holdings by purchasing 1,229 BTC at an average of approximately $88,568 per coin, totaling $108.8 million throu...

Dec 29, 2025 Finance

Tonix Pharmaceuticals Advances Lyme Disease Antibody Program and Secures Funding

New Developments on Long-Acting Monoclonal Antibody TNX-4800 and Strategic Financing Moves

Tonix Pharmaceuticals unveiled progress regarding its long-acting monoclonal antibody TNX-4800 targeting Lyme disease and finalized a $20 million fund...

Dec 29, 2025 Finance

Nvidia GTC 2026: Key Event for AI Innovation and Industry Insights

Mark March 16 for Nvidia’s pivotal AI conference highlighting next-gen technologies and strategic shifts

Nvidia, a frontrunner in the artificial intelligence sector and one of the largest global public companies, is hosting its annual GTC conference from ...

Dec 29, 2025 Finance

Novo Nordisk Lowers Wegovy Prices in China Amid Rising Competition

Strategic Price Reduction Aims to Maintain Market Share as Semaglutide Patent Nears Expiry

Novo Nordisk has initiated significant price cuts for its obesity medication Wegovy in China, reaching reductions of nearly 50% for the highest dose v...

Clearing Up 2025's AI Misconceptions: Progress, Safety, and Creativity
Dec 29, 2025 Technology News

Clearing Up 2025's AI Misconceptions: Progress, Safety, and Creativity

Addressing prevalent misunderstandings about artificial intelligence developments and capabilities in the current landscape

As artificial intelligence technology advances rapidly in 2025, several widespread misunderstandings persist regarding its progress, safety in autonom...

Dec 29, 2025 Finance

Alphabet Expands AI Infrastructure Capabilities with $4.75 Billion Intersect Acquisition

A Strategic Move to Enhance Energy Management and Data Center Efficiency in AI Development

Alphabet recently completed a significant acquisition by purchasing Intersect, a firm specializing in utility-scale renewable energy solutions for dat...

Dec 29, 2025 Finance

Analysts Adjust Valuations Across Biotech and Tech Sectors: Spotlight on Praxis Precision Medicines and Others

Recent price target revisions and rating changes reveal shifting market sentiment toward select Nasdaq and NYSE stocks

Several prominent Wall Street analysts have updated their price targets and ratings for a range of stocks, particularly within the biotech and technol...

Dec 29, 2025 Trade Ideas

Jumia (JMIA): A Turnaround in Motion — Tactical Long with Asymmetric Upside

Price momentum validated by volume; trade with size discipline — entry 11.25–12.00, stop 9.00, targets 16/22/30

Jumia's stock has moved from single-digit distress levels into a clear recovery phase. The rally has traction: heavy volume on breakouts, repeated new...

Trade Idea Long
Dec 29, 2025 Finance

Strategic Insights on Undervalued Stocks Heading into Year-End 2025

Analyzing Airbnb, Lululemon, and Alphabet: Navigating Growth, Valuation, and Market Opportunities

As 2025 draws to a close, investors and analysts weigh the prospects of select stocks viewed as undervalued opportunities within their respective sect...